NASDAQ:MRTX

Mirati Therapeutics (MRTX) Stock Forecast, Price & News

$43.56

-1.79 (-3.95%)

(As of 09/29/2023 ET)

Compare

Today's Range: $43.05
▼
$46.00
50-Day Range: $27.80
▼
$45.35
52-Week Range: $27.30
▼
$101.30

Volume: 1.32 million shs
Average Volume: 1.40 million shs
Market Capitalization: $2.55 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $55.85

Mirati Therapeutics MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.54 Rating Score
Upside/Downside: 28.2% Upside
$55.85 Price Target
Short Interest: Bearish
15.44% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.68
Upright™ Environmental Score
News Sentiment: 0.82
Based on 7 Articles This Week
Insider Trading: Acquiring Shares
$33.70 M Bought Last Quarter
Proj. Earnings Growth: Growing
From ($11.85) to ($10.60) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.56 out of 5 stars

Medical Sector

139th out of 972 stocks

Pharmaceutical Preparations Industry

47th out of 455 stocks

4.3

Analyst's Opinion

Consensus Rating
Mirati Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.54, and is based on 8 buy ratings, 4 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $55.85, Mirati Therapeutics has a forecasted upside of 28.2% from its current price of $43.56.
Amount of Analyst Coverage
Mirati Therapeutics has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.0

Short Interest

Percentage of Shares Shorted
15.44% of the outstanding shares of Mirati Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Mirati Therapeutics has a short interest ratio ("days to cover") of 7.
Change versus previous month
Short interest in Mirati Therapeutics has recently decreased by 4.33%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Mirati Therapeutics does not currently pay a dividend.
Dividend Growth
Mirati Therapeutics does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Mirati Therapeutics has received a 74.62% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Clinical research services for cancer", "Basic medical research services", and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Mirati Therapeutics is -0.68.

3.2

News and Social Media Coverage

News Sentiment
Mirati Therapeutics has a news sentiment score of 0.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for Mirati Therapeutics this week, compared to 3 articles on an average week.
Search Interest
Only 9 people have searched for MRTX on MarketBeat in the last 30 days. This is a decrease of -44% compared to the previous 30 days.
MarketBeat Follows
3 people have added Mirati Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Mirati Therapeutics insiders have bought 39,507.94% more of their company's stock than they have sold. Specifically, they have bought $33,700,022.00 in company stock and sold $85,084.00 in company stock.
Percentage Held by Insiders
Only 3.47% of the stock of Mirati Therapeutics is held by insiders.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Mirati Therapeutics are expected to grow in the coming year, from ($11.85) to ($10.60) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Mirati Therapeutics is -3.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Mirati Therapeutics is -3.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Mirati Therapeutics has a P/B Ratio of 2.52. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Mirati Therapeutics (NASDAQ:MRTX) Stock

Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. In addition, the company pipeline comprises the MRTX1719, an investigational synthetic lethal PRMT5 inhibitor designed to target the PRMT5/methylthioadensoine (MTA) complex and is in clinical development; MRTX0902, a selective SOS1 inhibitor that improves anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors, and is in clinical development; and MRTX1133, an investigational lead KRAS G12D compound. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and Zai Lab Ltd. to research, develop, manufacture, and commercialize adagrasib in various indications. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.

MRTX Price History

30 days | 90 days | 365 days | Advanced Chart

MRTX Stock News Headlines

October 1, 2023 | americanbankingnews.com

Mirati Therapeutics (NASDAQ:MRTX) Shares Down 3.7%

September 30, 2023 | americanbankingnews.com

Mirati Therapeutics (NASDAQ:MRTX) Given "Market Outperform" Rating at JMP Securities

October 1, 2023 | Stansberry Research (Ad)

Investing Legend Warns: NVIDIA is a "Delusion"

Irrational investment in this tech giant may have made it “too big to succeed” says this renowned expert. Read this before you buy shares.

September 28, 2023 | msn.com

Mirati stock climbs 10% ahead of data presentation, FDA meeting on rival drug

September 27, 2023 | finance.yahoo.com

Mirati To Present Updated Clinical Data at ESMO Congress 2023

September 24, 2023 | americanbankingnews.com

Mirati Therapeutics (NASDAQ:MRTX) Sees Strong Trading Volume

September 13, 2023 | benzinga.com

Massive Insider Trade At Mirati Therapeutics

September 13, 2023 | markets.businessinsider.com

Analysts Conflicted on These Healthcare Names: BioMarin Pharmaceutical (BMRN), Mirati Therapeutics (MRTX) and Opthea Limited Sponsored ADR (OPT)

October 1, 2023 | Stansberry Research (Ad)

Investing Legend Warns: NVIDIA is a "Delusion"

Irrational investment in this tech giant may have made it “too big to succeed” says this renowned expert. Read this before you buy shares.

September 11, 2023 | markets.businessinsider.com

Scotiabank Keeps Their Sell Rating on Mirati Therapeutics (MRTX)

August 29, 2023 | finance.yahoo.com

Mirati Therapeutics to Participate at the Morgan Stanley 21st Annual Global Healthcare Conference

August 28, 2023 | msn.com

Mirati: Expansion Of Adagrasib With sNDA And Combination Studies

August 23, 2023 | marketwatch.com

Mirati Therapeutics Taps Aaron Ondrey as CFO to Succeed Laurie Stelzer

August 23, 2023 | markets.businessinsider.com

Mirati Therapeutics CFO Laurie Stelzer Resigns

August 23, 2023 | msn.com

Mirati CFO leaving company in wake of CEO departure

August 22, 2023 | markets.businessinsider.com

JMP Securities Keeps Their Buy Rating on Mirati Therapeutics (MRTX)

August 19, 2023 | finance.yahoo.com

3 Under-the-Radar Biotech Stocks to Buy in 2023

August 16, 2023 | finance.yahoo.com

BOXER CAPITAL, LLC Boosts Stake in Mirati Therapeutics Inc

August 11, 2023 | msn.com

Citi upgrades Mirati to buy; cites valuation, leadership change

August 11, 2023 | msn.com

B. Riley Securities Upgrades Mirati Therapeutics (MRTX)

August 10, 2023 | seekingalpha.com

Mirati Therapeutics, Inc. 2023 Q2 - Results - Earnings Call Presentation

August 9, 2023 | markets.businessinsider.com

Piper Sandler Keeps Their Buy Rating on Mirati Therapeutics (MRTX)

August 9, 2023 | msn.com

Mirati Rockets 26% On A Bevy Of News In Cancer, A $300 Million Deal And Its CEO Exit

August 9, 2023 | markets.businessinsider.com

Mirati Therapeutics (MRTX) Has a New Rating from Barclays

August 9, 2023 | markets.businessinsider.com

Bank of America Securities Sticks to Their Hold Rating for Mirati Therapeutics (MRTX)

August 9, 2023 | msn.com

Mirati Therapeutics up 9% on pricing $300M upsized equity offering

August 9, 2023 | finance.yahoo.com

Mirati Therapeutics Announces Pricing of Upsized Public Offering

See More Headlines

Receive MRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mirati Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MRTX Company Calendar

Last Earnings: 8/08/2023
Today: 10/01/2023
Next Earnings (Estimated): 11/14/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:MRTX
CUSIP: N/A
CIK: 1576263
Web: www.mirati.com
Phone: (858) 332-3410
Fax: N/A
Employees: 587
Year Founded: 2013

Price Target and Rating

Average Stock Price Forecast: $55.85
High Stock Price Forecast: $83.00
Low Stock Price Forecast: $31.00
Forecasted Upside/Downside: +28.2%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.54
Research Coverage: 13 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($12.82)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-740,870,000.00
Net Margins: -2,709.33%
Pretax Margin: -2,707.47%
Return on Equity: -79.37%
Return on Assets: -66.23%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.85
Quick Ratio: 5.79

Sales & Book Value

Annual Sales: $12.44 million
Price / Sales: 205.19
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $17.31 per share
Price / Book: 2.52

Miscellaneous

Outstanding Shares: 58,600,000
Free Float: 56,570,000
Market Cap: $2.55 billion
Optionable: Optionable
Beta: 0.91

Social Links

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Dr. Charles M. Baum M.D. (Age 65)
Ph.D., Founder, Interim CEO, Pres, Head of R&D and Director
Comp: $1.07M

Dr. James G. Christensen Ph.D. (Age 55)
Exec. VP & Chief Scientific Officer
Comp: $1.76M

Ms. Laurie D. Stelzer M.B.A. (Age 55)
Consultant
Comp: $609.06k

Dr. Alan Bart Sandler M.D. (Age 66)
Exec. VP & Chief Medical Officer
Comp: $591k

Mr. Aaron Ondrey (Age 47)
Interim Chief Financial Officer

Ms. Betsy Gelfand CPA
Chief Accounting Officer, Principal Accounting Officer & VP of Fin.

Mr. John B. Moriarty Jr. (Age 55)
J.D., Chief Legal Officer

Mr. Peter Lee
Chief Compliance Officer

Mr. Michael E. Paolucci (Age 63)
Chief People Officer

Mr. Benjamin J. Hickey M.B.A. (Age 48)
Chief Commercial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

MRTX Stock - Frequently Asked Questions

Should I buy or sell Mirati Therapeutics stock right now?: 13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Mirati Therapeutics in the last twelve months. There are currently 1 sell rating, 4 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" MRTX shares.
View MRTX analyst ratings or view top-rated stocks.
What is Mirati Therapeutics' stock price forecast for 2023?: 13 Wall Street research analysts have issued twelve-month target prices for Mirati Therapeutics' shares. Their MRTX share price forecasts range from $31.00 to $83.00. On average, they expect the company's share price to reach $55.85 in the next twelve months. This suggests a possible upside of 28.2% from the stock's current price.
View analysts price targets for MRTX or view top-rated stocks among Wall Street analysts.
How have MRTX shares performed in 2023?: Mirati Therapeutics' stock was trading at $45.31 at the beginning of the year. Since then, MRTX shares have decreased by 3.9% and is now trading at $43.56.
View the best growth stocks for 2023 here.
When is Mirati Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our MRTX earnings forecast.
How were Mirati Therapeutics' earnings last quarter?: Mirati Therapeutics, Inc. (NASDAQ:MRTX) released its quarterly earnings data on Tuesday, August, 8th. The biotechnology company reported ($3.04) earnings per share for the quarter, beating analysts' consensus estimates of ($3.23) by $0.19. The biotechnology company had revenue of $13.70 million for the quarter, compared to the consensus estimate of $13.17 million. Mirati Therapeutics had a negative net margin of 2,709.33% and a negative trailing twelve-month return on equity of 79.37%. The firm's quarterly revenue was up 153.7% on a year-over-year basis. During the same period in the prior year, the firm posted ($3.18) EPS.
What other stocks do shareholders of Mirati Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Mirati Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), AbbVie (ABBV), QUALCOMM (QCOM), BioMarin Pharmaceutical (BMRN), Micron Technology (MU), Netflix (NFLX), Block (SQ), Alibaba Group (BABA) and DocuSign (DOCU).

What is Mirati Therapeutics' stock symbol?: Mirati Therapeutics trades on the NASDAQ under the ticker symbol "MRTX."
How do I buy shares of Mirati Therapeutics?: Shares of MRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Mirati Therapeutics' stock price today?: One share of MRTX stock can currently be purchased for approximately $43.56.
How much money does Mirati Therapeutics make?: Mirati Therapeutics (NASDAQ:MRTX) has a market capitalization of $2.55 billion and generates $12.44 million in revenue each year. The biotechnology company earns $-740,870,000.00 in net income (profit) each year or ($12.82) on an earnings per share basis.
How many employees does Mirati Therapeutics have?: The company employs 587 workers across the globe.
Does Mirati Therapeutics have any subsidiaries?: The following companies are subsidiares of Mirati Therapeutics: MethylGene, MethylGene Inc., and Mirati Therapeutics B.V..
Read More
How can I contact Mirati Therapeutics?: Mirati Therapeutics' mailing address is 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.mirati.com. The biotechnology company can be reached via phone at (858) 332-3410 or via email at ir@mirati.com.

This page (NASDAQ:MRTX) was last updated on 10/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Mirati Therapeutics (MRTX) Stock Forecast, Price & News

Mirati Therapeutics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Mirati Therapeutics (NASDAQ:MRTX) Stock

MRTX Price History

MRTX Stock News Headlines

MRTX Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

MRTX Stock - Frequently Asked Questions

Overall MarketRank^™